Percheron Therapeutics Ltd. (ATHJF)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 20, 2025

$0.01

P/E Ratio

N/A

Market Cap

$6.08M

Jan 29, 2024Mar 1, 2024Apr 5, 2024May 9, 2024Jun 13, 2024Jul 17, 2024Aug 20, 2024Sep 25, 2024Oct 30, 2024Dec 3, 2024Jan 20, 2025$0.00$10.00
  • ONT
Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

Metrics

Overview

  • HQMelbourne, VI
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerATHJF
  • Price$0.00559-0.02%

Trading Information

  • Market cap$6.08M
  • Float72.36%
  • Average Daily Volume (1m)20,910,750
  • Average Daily Volume (3m)20,040,428
  • EPS-$0.01

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$11.92M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$14.80M
  • EV$38.19M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.87
Documents